Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodesix, Inc. (BDSX) SEC filings page on Stock Titan brings together the company’s official disclosures as a Nasdaq-listed diagnostic solutions company. Through its reports to the U.S. Securities and Exchange Commission, Biodesix provides detail on its diagnostic testing and development services businesses, capital structure, and material corporate events.
Investors can use this page to access current and historical filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe revenue from Lung Diagnostics and Development Services, operating metrics, and risk factors relevant to a diagnostics and health care business. These core filings typically discuss Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as the company’s work with biopharmaceutical and life sciences partners.
Biodesix also files Forms 8-K to report specific material events. Recent 8-K filings document actions such as a one-for-twenty reverse stock split of the company’s common stock, the related amendment to its certificate of incorporation, elimination of a preferred stock series, and confirmation that the company regained compliance with Nasdaq’s minimum bid price requirement. Other 8-Ks furnish press releases announcing quarterly financial and operating results.
On this page, users can review insider and capital structure-related filings when available, including information about changes to equity, preferred stock designations, and other securities. These documents help clarify how corporate actions affect common stockholders and outstanding awards or warrants.
Stock Titan enhances access to Biodesix filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussions of revenue composition, diagnostic and development services, stock listing matters, and significant corporate changes. Real-time updates from the EDGAR system ensure that new Biodesix 10-K, 10-Q, 8-K, and related filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full regulatory text.
Biodesix, Inc. President & CEO Scott Hutton reported equity award activity and a related share sale. On February 9, 2026, he acquired 9,998 shares of Common Stock through the exercise of restricted stock units (RSUs), bringing his direct Common Stock holdings to 48,972 shares.
On February 10, 2026, 3,559 Common Shares were sold in an open-market transaction at a weighted average price of $10.0841 to cover taxes due upon RSU vesting, leaving him with 45,413 Common Shares held directly. RSU activity included the conversion of 610 RSUs that fully vested and 9,388 RSUs that remain outstanding, with vesting schedules tied to continued service and figures adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc. CFO Robin Harper Cowie reported equity compensation activity tied to restricted stock units (RSUs). On February 9, 2026, RSUs were converted into 2,584 shares of Common Stock, and RSU balances were updated, including 2,426 unvested RSUs after adjustment for a prior reverse split.
On February 10, 2026, Cowie executed an automatic open-market sale of 941 Common shares at a weighted average price of $10.0841 to cover taxes upon RSU vesting, leaving 15,297 Common shares held directly.
Biodesix Inc. Chief Development Officer Gary Anthony Pestano reported equity transactions involving company stock. On February 9, 2026, he acquired 1,481 shares of Common Stock through the exercise/conversion of restricted stock units (RSUs), bringing his direct holdings to 9,927 shares.
On February 10, 2026, 540 shares of Common Stock were sold at a weighted average price of $10.0841 per share, automatically to cover taxes upon RSU vesting. After this tax-related sale, Pestano directly owned 9,387 shares of Biodesix Common Stock. The filing also notes RSU grants that vest over time and that the reported RSU numbers reflect a one-for-twenty reverse stock split effective September 15, 2025.
Jack W. Schuler has updated his beneficial ownership in Biodesix, Inc. through Amendment No. 10 to his Schedule 13D. He now reports beneficial ownership of 2,333,945 shares of Biodesix common stock, representing about 24% of the outstanding shares, based on 9,685,789 shares outstanding plus 20,735 shares he can acquire within 60 days.
Recent open-market activity includes purchases through the Jack W. Schuler Living Trust of 82,465 shares on January 22, 2026 at a weighted average price of $10.9569, 80,000 shares on January 23, 2026 at $11.8084, and 20,000 shares on January 26, 2026 at $11.8032 per share. His reported holdings comprise 4,156 option shares and 16,579 RSU shares exercisable or settling within 60 days, 1,563,210 shares held by the Living Trust (about 16.1% of the class), and 750,000 shares held by the 2025 GRAT (about 7.7% of the class). Schuler serves as sole trustee of both entities and transitioned to emeritus director status at the May 20, 2025 annual meeting.
Biodesix Inc. reported insider share purchases by entities associated with major shareholder Jack W. Schuler. On January 23, 2026, the Jack W. Schuler Living Trust bought 80,000 shares of Biodesix common stock at a weighted average price of $11.8084, and on January 26, 2026 it bought an additional 20,000 shares at a weighted average price of $11.8032. After these transactions, the Living Trust held 1,563,210 shares of common stock, and the Jack W. Schuler 2025 GRAT held 750,000 shares, both reported as indirectly owned. The prices reflect multiple individual trades within stated ranges, and Schuler is disclosed as the sole trustee of both trusts.
Biodesix, Inc. (BDSX) received a new ownership disclosure from Telemark-related entities reporting a passive stake in its common stock. Telemark Asset Management, LLC, Telemark Fund, LP, and individual investor Colin S. McNay together report beneficial ownership of 427,824 shares of Biodesix common stock, which they state represents approximately 5.4% of the outstanding shares. All reported shares are held with shared power to vote and dispose, and none with sole voting or dispositive power. The filers certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Biodesix, but rather as a passive investment.
Biodesix Inc. 10% owner Jack W. Schuler, through his living trust, increased his indirect stake in the company. On January 22, 2026, the Jack W. Schuler Living Trust purchased 82,465 shares of Biodesix common stock in open-market transactions at a weighted average price of $10.9569 per share, with individual trades ranging from $10.675 to $11.10. Following this purchase, the living trust held 1,463,210 shares of Biodesix common stock indirectly for Schuler as sole trustee. A separate vehicle, the Jack W. Schuler 2025 GRAT, is shown as indirectly holding an additional 750,000 shares of Biodesix common stock, also with Schuler as sole trustee.
Telemark Asset Management, Telemark Fund and Colin McNay have filed an Amendment No. 1 to their Schedule 13G for Biodesix, Inc., which they state is a final, “exit” filing. The reporting persons may be deemed to beneficially own 327,824 shares of Biodesix common stock, representing approximately 4.1% of the outstanding shares as of the event date.
All 327,824 shares are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Biodesix, but instead under the passive ownership standard applicable to Schedule 13G.
Biodesix, Inc. insider Chris Vazquez, the Chief Accounting Officer, reported routine equity transactions involving restricted stock units (RSUs) and related tax sales. On January 15, 2026, 219 RSUs vested and were converted into an equal number of shares of Biodesix common stock at an exercise price of $0, consistent with each RSU representing one share. On January 16, 2026, 83 of these common shares were automatically sold at a weighted average price of $8.1493 per share to cover taxes due upon vesting, with prices ranging from $8.10 to $8.28. Following these transactions, Vazquez directly held 1,072 shares of common stock and 436 RSUs, which vest in four equal annual installments from January 15, 2024. The reported share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc's Chief Development Officer, Gary Pestano, reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units converted into 805 shares of Biodesix common stock at an exercise price of
On January 16, 2026, 298 shares of common stock were sold at a weighted average price of